Overview
- The CONNECT randomized trial, presented Saturday at the American Diabetes Association Scientific Sessions, assigned 283 adults with type 2 diabetes not using insulin to either the Dexcom G7 or routine self‑monitoring for 26 weeks.
- Participants using the G7 had a mean HbA1c drop from 8.8% to 7.2% (−1.6%) versus 8.7% to 8.0% (−0.7%) in controls, a between‑group difference of 0.9 percentage points that reached statistical significance.
- G7 users spent about five more hours per day in the 70–180 mg/dL target range, with improvements appearing within one week and sustained through 26 weeks.
- No serious adverse events were reported and CGM users reported greater satisfaction and less diabetes distress; a six‑month extension is under way to test whether benefits last to 12 months.
- Dexcom funded the multicenter primary‑care trial and company leaders have urged broader access, which means payers and guideline panels will likely weigh these results against the need for independent replication and longer‑term durability data.